Literature DB >> 17562487

Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections.

Nancy Goebl1, Brian Berridge, Victor J Wroblewski, Patricia L Brown-Augsburger.   

Abstract

A sensitive method has been developed for the identification and assessment of phosphorothioate oligonucleotide accumulation in dosed animal tissues using an in situ hybridization approach, which is both sequence specific yet adaptable to every antisense oligonucleotide (ASO), which has been tested to date. Hybridization is accomplished using a digoxigenin-tailed oligonucleotide probe complementary to the ASO target sequence on routinely processed paraffin sections which have been pretreated with a mild target retrieval solution. The DIG-labeled probe is amplified first with an anti-DIG:FITC antibody conjugate followed by an anti:FITC Alexa 488 antibody, then visualized using FITC epifluorescence microscopy. Fluorescent labeling of ASO drug in tissue sections by this method confirms that H&E basophilia previously observed in dosed tissues represents largely intact ASO. However, the fluorescent method enables a wider assessment of tissue distribution in a variety of tissue types due to increased sensitivity and lower signal to noise than can be obtained through an examination of H&E stained tissue sections alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562487     DOI: 10.1080/01926230701338958

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  6 in total

Review 1.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

2.  Gender-Specific Amelioration of SMA Phenotype upon Disruption of a Deep Intronic Structure by an Oligonucleotide.

Authors:  Matthew D Howell; Eric W Ottesen; Natalia N Singh; Rachel L Anderson; Ravindra N Singh
Journal:  Mol Ther       Date:  2017-04-13       Impact factor: 11.454

Review 3.  Aptamer Therapeutics in Cancer: Current and Future.

Authors:  Yoshihiro Morita; Macall Leslie; Hiroyasu Kameyama; David E Volk; Takemi Tanaka
Journal:  Cancers (Basel)       Date:  2018-03-19       Impact factor: 6.639

Review 4.  Aptamers as therapeutics.

Authors:  Anthony D Keefe; Supriya Pai; Andrew Ellington
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 5.  Delivery is key: lessons learnt from developing splice-switching antisense therapies.

Authors:  Caroline Godfrey; Lourdes R Desviat; Bård Smedsrød; France Piétri-Rouxel; Michela A Denti; Petra Disterer; Stéphanie Lorain; Gisela Nogales-Gadea; Valentina Sardone; Rayan Anwar; Samir El Andaloussi; Taavi Lehto; Bernard Khoo; Camilla Brolin; Willeke Mc van Roon-Mom; Aurélie Goyenvalle; Annemieke Aartsma-Rus; Virginia Arechavala-Gomeza
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

Review 6.  Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.

Authors:  Fadwa Odeh; Hamdi Nsairat; Walhan Alshaer; Mohammad A Ismail; Ezaldeen Esawi; Baraa Qaqish; Abeer Al Bawab; Said I Ismail
Journal:  Molecules       Date:  2019-12-18       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.